BioN­Tech de­liv­ered a com­pelling piece of ev­i­dence Mon­day sup­port­ing the de­vel­op­ment of its CT­LA-4 an­ti­body go­tis­to­bart in lung can­cer.

Pre­vi­ous­ly treat­ed lung can­cer pa­tients who...

GSK is clos­ing a fac­to­ry in Ger­many and lay­ing off about 650 work­ers as de­mand for egg-based flu vac­cines de­clines, a spokesper­son told End­points News...

As more rare dis­ease treat­ments make their way to the FDA, the agency on Mon­day called for fur­ther out­side in­put as it grap­ples with how...

In a brand re­boot, No­vo Nordisk is short­en­ing its name and adopt­ing a new cul­ture strat­e­gy af­ter a se­ries of set­backs this year.

From Mon­day...

Schol­ar Rock has won FDA ap­proval for its drug treat­ing a rare mus­cle-wast­ing dis­ease, af­ter fac­ing de­lays due to a trou­bled man­u­fac­tur­ing fac­to­ry.

The in­jectable...

Defini­um Ther­a­peu­tics re­port­ed re­sults Mon­day for its third Phase 3 read­out this year on its oral LSD can­di­date, called DT120, and is gear­ing up for...